The Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® ...

The following is a summary of "Advances and challenges in targeted therapies for HER2-amplified colorectal cancer," published ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Ipatasertib combined with fulvestrant significantly extends progression-free survival in ER-positive, HER2-negative ...